207 related articles for article (PubMed ID: 8993512)
1. Schedule-dependent efficacy of camptothecins in models of human cancer.
Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA
Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512
[No Abstract] [Full Text] [Related]
2. Clinical trials using irinotecan.
Houghton PJ; Santana VM
J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
[No Abstract] [Full Text] [Related]
3. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
4. CPT-11: a novel antitumor drug.
Armand JP
Jpn J Cancer Res; 1994 Aug; 85(8):inside front cover. PubMed ID: 7928619
[No Abstract] [Full Text] [Related]
5. Topoisomerase-I inhibitors in the management of colon cancer.
Willson JK
Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519
[No Abstract] [Full Text] [Related]
6. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
[TBL] [Abstract][Full Text] [Related]
7. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Lavergne O; Bigg DC
Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I inhibition: a new target or new missiles?
Verweij J; Schellens JH
Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815
[No Abstract] [Full Text] [Related]
9. Camptothecins: new enthusiasm for an old drug.
Rowe PM
Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402
[No Abstract] [Full Text] [Related]
10. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
Agrawal S; Kandimalla ER; Yu D; Hollister BA; Chen SF; Dexter DL; Alford TL; Hill B; Bailey KS; Bono CP; Knoerzer DL; Morton PA
Int J Oncol; 2001 May; 18(5):1061-9. PubMed ID: 11295057
[TBL] [Abstract][Full Text] [Related]
12. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
de Jonge MJ; Sparreboom A; Verweij J
Cancer Treat Rev; 1998 Jun; 24(3):205-20. PubMed ID: 9767735
[No Abstract] [Full Text] [Related]
13. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
16. Rubitecan.
Clark JW
Expert Opin Investig Drugs; 2006 Jan; 15(1):71-9. PubMed ID: 16370935
[TBL] [Abstract][Full Text] [Related]
17. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
18. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
19. Camptothecins: a review of their development and schedules of administration.
O'Leary J; Muggia FM
Eur J Cancer; 1998 Sep; 34(10):1500-8. PubMed ID: 9893620
[TBL] [Abstract][Full Text] [Related]
20. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]